{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:32:54Z","timestamp":1793950374266,"version":"4.8.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Electrocardiology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jelectrocard.2026.154440","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:52:31Z","timestamp":1787673151000},"page":"154440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Progressive electrocardiographic remodeling despite Tafamidis therapy in transthyretin amyloid cardiomyopathy (ATTR-CM)"],"prefix":"10.1016","volume":"99","author":[{"given":"Lilou","family":"Escorbiac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Weeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"K\u00e4\u00e4b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Massberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian aus dem","family":"Siepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie K.","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jelectrocard.2026.154440_bb0005","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jelectrocard.2026.154440_bb0010","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaccao.2022.08.007","article-title":"Low QRS voltages in cardiac amyloidosis: clinical correlates and prognostic value","volume":"4","author":"Cipriani","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10.1016\/j.jelectrocard.2026.154440_bb0015","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1002\/ehf2.14082","article-title":"Electrical cardioversion of atrial arrhythmias with cardiac amyloidosis in the era of direct oral anticogulants","volume":"9","author":"Touboul","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10.1016\/j.jelectrocard.2026.154440_bb0020","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/ehf2.14655","article-title":"Novel electrocardiographic criteria may render possible the more accurate recognition of cardiac amyloidosis","volume":"11","author":"Vereckei","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10.1016\/j.jelectrocard.2026.154440_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/jcm15062201","article-title":"Prediagnostic electrocardiographic abnormalities in transthyretin amyloid cardiomyopathy: a longitudinal observational study","volume":"15","author":"Venkateshvaran","year":"2026","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.jelectrocard.2026.154440_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102766","article-title":"Monitoring disease progression in patients with transthyretin amyloid cardiomyopathy","volume":"14","author":"Garcia-Pavia","year":"2026","journal-title":"JACC Heart Fail"},{"issue":"30","key":"10.1016\/j.jelectrocard.2026.154440_bb0035","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jelectrocard.2026.154440_bb0040","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"9","key":"10.1016\/j.jelectrocard.2026.154440_bb0045","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10.1016\/j.jelectrocard.2026.154440_bb0050","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00392-025-02680-x","article-title":"QTc interval prolongation as a marker of disease stage in transthyretin cardiac amyloidosis","volume":"115","author":"Tsampras","year":"2026","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"10.1016\/j.jelectrocard.2026.154440_bb0055","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jacc.2025.09.004","article-title":"Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance","volume":"87","author":"Writing","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jelectrocard.2026.154440_bb0060","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cjco.2025.05.012","article-title":"Longitudinal changes in multiple cardiac biomarkers in transthyretin amyloidosis cardiomyopathy patients treated vs untreated with Tafamidis","volume":"7","author":"Shahi","year":"2025","journal-title":"CJC Open"},{"issue":"2","key":"10.1016\/j.jelectrocard.2026.154440_bb0065","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ehf2.14684","article-title":"Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis","volume":"12","author":"Argiro","year":"2025","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10.1016\/j.jelectrocard.2026.154440_bb0070","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jelectrocard.2026.154440_bb0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jelectrocard.2026.154440_bb0080","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Journal of Electrocardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022073626002578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022073626002578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:03:17Z","timestamp":1790406197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022073626002578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":16,"alternative-id":["S0022073626002578"],"URL":"https:\/\/doi.org\/10.1016\/j.jelectrocard.2026.154440","relation":{},"ISSN":["0022-0736"],"issn-type":[{"value":"0022-0736","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive electrocardiographic remodeling despite Tafamidis therapy in transthyretin amyloid cardiomyopathy (ATTR-CM)","name":"articletitle","label":"Article Title"},{"value":"Journal of Electrocardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jelectrocard.2026.154440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"154440"}}